UNITED THERAPEUTICS CORP (UTHR) Stock Fundamental Analysis
USA - NASDAQ:UTHR - US91307C1027 - Common Stock
438.66 USD
-6.77 (-1.52%)
435.932 USD
-2.73 (-0.62%)
UTHR gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. UTHR gets an excellent profitability rating and is at the same time showing great financial health properties. UTHR scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, UTHR could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year UTHR was profitable.
UTHR had a positive operating cash flow in the past year.
In the past 5 years UTHR has always been profitable.
Each year in the past 5 years UTHR had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 17.30%, UTHR belongs to the top of the industry, outperforming 96.07% of the companies in the same industry.
UTHR has a Return On Equity of 19.30%. This is amongst the best in the industry. UTHR outperforms 95.51% of its industry peers.
With an excellent Return On Invested Capital value of 17.33%, UTHR belongs to the best of the industry, outperforming 96.82% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for UTHR is in line with the industry average of 15.51%.
The 3 year average ROIC (14.96%) for UTHR is below the current ROIC(17.33%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROIC | 17.33% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
1.3 Margins
The Profit Margin of UTHR (40.65%) is better than 98.13% of its industry peers.
In the last couple of years the Profit Margin of UTHR has grown nicely.
Looking at the Operating Margin, with a value of 48.65%, UTHR belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
UTHR's Operating Margin has improved in the last couple of years.
UTHR's Gross Margin of 88.59% is amongst the best of the industry. UTHR outperforms 90.07% of its industry peers.
UTHR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% |
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), UTHR is creating value.
Compared to 1 year ago, UTHR has less shares outstanding
Compared to 5 years ago, UTHR has more shares outstanding
The debt/assets ratio for UTHR has been reduced compared to a year ago.
2.2 Solvency
UTHR has an Altman-Z score of 19.04. This indicates that UTHR is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 19.04, UTHR belongs to the top of the industry, outperforming 89.33% of the companies in the same industry.
UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.04 |
ROIC/WACC1.99
WACC8.69%
2.3 Liquidity
A Current Ratio of 6.40 indicates that UTHR has no problem at all paying its short term obligations.
UTHR has a better Current ratio (6.40) than 66.67% of its industry peers.
UTHR has a Quick Ratio of 6.07. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
UTHR's Quick ratio of 6.07 is fine compared to the rest of the industry. UTHR outperforms 64.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 |
3. Growth
3.1 Past
UTHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.90%, which is quite good.
The Earnings Per Share has been growing by 16.88% on average over the past years. This is quite good.
UTHR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.50%.
Measured over the past years, UTHR shows a quite strong growth in Revenue. The Revenue has been growing by 14.71% on average per year.
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
3.2 Future
UTHR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.54% yearly.
The Revenue is expected to grow by 10.10% on average over the next years. This is quite good.
EPS Next Y14.15%
EPS Next 2Y9.73%
EPS Next 3Y7.6%
EPS Next 5Y13.54%
Revenue Next Year11.56%
Revenue Next 2Y8.55%
Revenue Next 3Y8.2%
Revenue Next 5Y10.1%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 16.62, which indicates a correct valuation of UTHR.
95.88% of the companies in the same industry are more expensive than UTHR, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of UTHR to the average of the S&P500 Index (26.11), we can say UTHR is valued slightly cheaper.
UTHR is valuated correctly with a Price/Forward Earnings ratio of 14.81.
Based on the Price/Forward Earnings ratio, UTHR is valued cheaper than 95.13% of the companies in the same industry.
UTHR is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.55, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.62 | ||
| Fwd PE | 14.81 |
4.2 Price Multiples
UTHR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. UTHR is cheaper than 96.63% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, UTHR is valued cheaply inside the industry as 95.51% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.77 | ||
| EV/EBITDA | 9.94 |
4.3 Compensation for Growth
UTHR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of UTHR may justify a higher PE ratio.
PEG (NY)1.17
PEG (5Y)0.98
EPS Next 2Y9.73%
EPS Next 3Y7.6%
5. Dividend
5.1 Amount
No dividends for UTHR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
438.66
-6.77 (-1.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.47%
Inst Owner Change-1.79%
Ins Owners1.76%
Ins Owner Change4.02%
Market Cap19.84B
Revenue(TTM)3.13B
Net Income(TTM)1.27B
Analysts80.91
Price Target499.6 (13.89%)
Short Float %4.58%
Short Ratio2.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.9%
Min EPS beat(2)-9.46%
Max EPS beat(2)-2.35%
EPS beat(4)0
Avg EPS beat(4)-4.02%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)2
Avg EPS beat(8)-2.47%
EPS beat(12)5
Avg EPS beat(12)-3.15%
EPS beat(16)7
Avg EPS beat(16)-2.98%
Revenue beat(2)0
Avg Revenue beat(2)-3.23%
Min Revenue beat(2)-3.81%
Max Revenue beat(2)-2.65%
Revenue beat(4)1
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-3.81%
Max Revenue beat(4)6.71%
Revenue beat(8)5
Avg Revenue beat(8)1.56%
Revenue beat(12)7
Avg Revenue beat(12)1.27%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)5.67%
PT rev (3m)28.58%
EPS NQ rev (1m)-0.78%
EPS NQ rev (3m)2.99%
EPS NY rev (1m)0.07%
EPS NY rev (3m)-1.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.33%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)-0.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.62 | ||
| Fwd PE | 14.81 | ||
| P/S | 6.34 | ||
| P/FCF | 17.77 | ||
| P/OCF | 12.75 | ||
| P/B | 3.01 | ||
| P/tB | 3.06 | ||
| EV/EBITDA | 9.94 |
EPS(TTM)26.39
EY6.02%
EPS(NY)29.62
Fwd EY6.75%
FCF(TTM)24.68
FCFY5.63%
OCF(TTM)34.41
OCFY7.84%
SpS69.17
BVpS145.7
TBVpS143.12
PEG (NY)1.17
PEG (5Y)0.98
Graham Number294.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROCE | 22.37% | ||
| ROIC | 17.33% | ||
| ROICexc | 29.21% | ||
| ROICexgc | 30.07% | ||
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% | ||
| FCFM | 35.69% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexgc growth 3Y23.22%
ROICexgc growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 533.09% | ||
| Cap/Sales | 14.06% | ||
| Interest Coverage | 81.39 | ||
| Cash Conversion | 96.99% | ||
| Profit Quality | 87.79% | ||
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 | ||
| Altman-Z | 19.04 |
F-Score8
WACC8.69%
ROIC/WACC1.99
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
EPS Next Y14.15%
EPS Next 2Y9.73%
EPS Next 3Y7.6%
EPS Next 5Y13.54%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
Revenue Next Year11.56%
Revenue Next 2Y8.55%
Revenue Next 3Y8.2%
Revenue Next 5Y10.1%
EBIT growth 1Y12.9%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year18.1%
EBIT Next 3Y5.05%
EBIT Next 5Y-4.6%
FCF growth 1Y46.07%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y62.87%
OCF growth 3Y30.42%
OCF growth 5YN/A
UNITED THERAPEUTICS CORP / UTHR FAQ
What is the fundamental rating for UTHR stock?
ChartMill assigns a fundamental rating of 7 / 10 to UTHR.
Can you provide the valuation status for UNITED THERAPEUTICS CORP?
ChartMill assigns a valuation rating of 7 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Undervalued.
What is the profitability of UTHR stock?
UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for UTHR stock?
The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 16.62 and the Price/Book (PB) ratio is 3.01.
What is the financial health of UNITED THERAPEUTICS CORP (UTHR) stock?
The financial health rating of UNITED THERAPEUTICS CORP (UTHR) is 9 / 10.